Pall Corporation and Single Use Support Partner to Safeguard Storage and Transport Critical Biopharmaceuticals

December 16, 2020

Pall Corporation, a global leader in filtration, separation, and purification, announced a strategic partnership with Single Use Support GmbH, a leading provider of an innovative, end-to-end solution for safe handling of biologics from bulk manufacturing to fill-finish.

Pall Corporation will provide significant investment and partner with Single Use Support to distribute the RoSS platform which enhances Pall’s integrated solutions and will make the RoSS platform more accessible to Biopharma customers around the globe.

“Safe and reliable management of drug substances is a challenge for many Pall customers. Through our partnership with Single Use Support, Pall will be able to offer the Biopharma industry a fully validated end-to-end solution, which will enable our customers to bring life-saving drugs to the patient in a more efficient way,” explained Ed Hoare, Vice President and General Manager, Pall Corporation.

Single-Use Support’s RoSS platform consists of an innovative workflow solution, combining robust RoSS shells to protect single-use biocontainers, such as Pall’s Allegro™ biocontainer bags, throughout the process with systems allowing automated filling, controlled freezing/thawing and safe transportation.

“Through high-value liquid management systems, we help our customers safeguard a step that, while inefficient, is mission-critical in bioprocessing,” said Johannes Kirchmair, co-founder and Managing Director of Single Use Support.

Thomas Wurm, co-founder and Managing Director of Single Use Support further explained, “Pall is a global science and technology innovator and shares our mission to help customers solve complex challenges to improve quality of life around the world. Pall Corporation holds an unparalleled leadership position in bioprocessing technologies. Through our partnership, our innovative solution will become more accessible to customers worldwide.”

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution